Oncology

Fractional CO2 laser therapy may offer a nonhormonal treatment to improve sexual function in survivors of breast cancer with genitourinary syndrome of menopause.

The FDA has approved trilaciclib (Cosela) to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

Investigators found that poor diets are particularly common among adult cancer survivors who have significant sociodemographic disparities, including those who have less formal education and those who are overweight.

Data show that 1 in 5 men and women worldwide develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease, according to the study.

The efficacy results demonstrated that there were 4 patients with confirmed partial response, and an additional 3 patients had stable disease lasting 16 weeks or longer.

A biologics license application has been submitted to the FDA for the accelerated approval of tisotumab vedotin for use in patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic the next steps for his CAEL-101 findings, a treatment for patients living with amyloid light chain amyloidosis.

Libtayo is the first treatment to show a clinical benefit in patients with advanced basal cell carcinoma after hedgehog pathway inhibitor therapy in a pivotal trial.

The findings suggest that the prevalence of these conditions among cancer survivors is nearly 40% higher than that in the general population.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic his recent CAEL-101 findings, and how it can help shape treatment for patients living with amyloid light chain amyloidosis.

The BTD designations for asciminib were based on the phase 3, multicenter, open-label, randomized ASCEMBL trial and a phase I trial that included patients with Ph+ CML, some of them harboring the T315I mutation.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about what CAEL-101 is, how it works, and how it is used to treat patients with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers, about how the COVID-19 pandemic is going to impact cancer mortality.

MET exon 14 skipping alterations occur in approximately 3% of adenocarcinomas and approximately 2% in other lung neoplasms, making them attractive potential targets for lung cancer treatment.

The collaboration begins today, which is also World Cancer Day, and the organizations will be working together to develop and share resources and educational information for the medically integrated oncology pharmacy team.

The findings suggest pre-diagnosis aspirin use might help reduce CRC mortality in the overall population by limiting metastatic spread of colorectal tumors before diagnosis.

Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers, about how screening can help reduce cancer deaths.

Despite rising cancer death rates during the coronavirus disease 2019 (COVID-19) pandemic, Randall A. Oyer, MD, said it's not too late to reverse it.

The guidelines recommend discontinuing routine mammograms for survivors with a life expectancy under 5 years, considering stopping screening for those with a 5- to 10-year life expectancy, and continuing mammography for those whose life expectancy is greater than 10 years.

Radiologists should be aware of pulmonary artery thrombosis so that they can work with pharmacists to facilitate accurate diagnoses and management techniques.

Research highlights the need for cardiologists and cardio-oncologists to be involved in the treatment of men with breast cancer due to common risk factors and potential cardiotoxic effects of treatment.

Numerous therapeutic options are available for acute myeloid leukemia, but more research is needed to determine how best to use them.

Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trials.

Data from a phase 1b/2 trial investigating the treatment of CCA with the combination of silmitasertib plus gemcitabine and cisplatin in comparison with gemcitabine and cisplatin found a statistically significant difference.

The treatment of 5-fluorouracil with levofolinate and irinotecan was found to be well-tolerated and effective as a second-line treatment for patients with gemcitabine-refractory advanced pancreatic cancer.

If approved, the biosimilar will be indicated for use in metastatic colorectal cancer, nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and metastatic cervical cancer.

Preclinical models have also shown that treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival, according to the study authors.